Content discovery platform

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Retrieved on: 
Saturday, November 4, 2023
Research, Arm, Society for Immunotherapy of Cancer, Intelligence, HSV, Therapy, Enlightenment, ICI, Herpes simplex virus, CADL, MD, Doctor of Philosophy, Nature, SITC, Immunotherapy, Neoplasm, Biology, Drug discovery, Machine learning, Annual general meeting, Tumor microenvironment, Bone marrow, Patient, Toxicity, Content discovery platform, Vaccine, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.

Key Points: 
  • “We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • “Tumor resistance to immunotherapy is driven by multiple mechanisms, which are heterogeneous in nature,” said Francesca Barone, MD, PhD, Chief Scientific Officer at Candel.
  • “The Alpha-201-macro1 preclinical data presented today support the utility of local delivery of an immunologically active, multimodal agent as a potential alternative to systemic therapy.
  • We are excited to leverage the enLIGHTEN™ Discovery Platform to optimize the immunostimulatory payload of this agent for activation of innate immune surveillance with the goal of maximizing its therapeutic potential.”
    Further details from the posters are available on the Candel website at: www.candeltx.com/media

Machine Discovery Secures $6 Million to Deliver AI Tools For Semiconductor Design

Retrieved on: 
Wednesday, September 27, 2023
University, UCSB Physics Department, CSO, BGF, OXFORD, Content discovery platform, Machine learning, Engineering, Growth, Video game, Manufacturing

First core application in analog semiconductor design, delivering instant prediction capability for integrated circuit design as a companion to existing tools and simulators.

Key Points: 
  • First core application in analog semiconductor design, delivering instant prediction capability for integrated circuit design as a companion to existing tools and simulators.
  • By 2026, Machine Discovery will cut the analog semiconductor product development cycle in half.
  • OXFORD, England and SANTA CLARA, Calif., Sept. 27, 2023 /PRNewswire/ -- Machine Discovery, a software company which uses machine learning technology to accelerate compute-intensive optimization and simulation tasks, has secured $6 million of funding.
  • Bijan Kiani, CEO of Machine Discovery, said: "Machine Discovery is pioneering the use of machine learning to reduce product development cycles in a variety of sectors.

CoreLogic Revolutionizes Data Access and Insights For Mortgage Lenders

Retrieved on: 
Wednesday, July 12, 2023
Commercial Building & Real Estate, Construction & Property, Data Analytics, Finance, Banking, Professional Services, Other Construction & Property, Residential Building & Real Estate, CoreLogic, Geography, Content discovery platform, Risk, Real estate

CoreLogic®, a leading provider specializing in property information, analytics, and data-enabled solutions, has announced an enhancement to the CoreLogic Discovery Platform™.

Key Points: 
  • CoreLogic®, a leading provider specializing in property information, analytics, and data-enabled solutions, has announced an enhancement to the CoreLogic Discovery Platform™.
  • With the recent enhancement, the platform now offers pre-designed solutions that assist mortgage lenders with turning data into valuable insights.
  • This update allows for faster decision-making and improved business outcomes, providing clients immediate access to actionable insights.
  • “A year later, we are proud to continue evolving this transformative technology for more mortgage lenders, including those without access to data scientists, to enable them to compete more effectively in today’s challenging marketplace,” continued Mateti.

Genomill and Finland's Cancer Research Flagship iCAN Partner To Improve Cancer Detection Using an Extensive Biobank Cohort

Retrieved on: 
Tuesday, June 13, 2023
DNA, Partnership, Finnish, Cancer, ICAN, MRD, Plasma, Patient, Content discovery platform, Biobank, Blood, Disease, Medical imaging

HELSINKI, June 13, 2023 /PRNewswire/ -- Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.

Key Points: 
  • HELSINKI, June 13, 2023 /PRNewswire/ -- Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.
  • Genomill's proprietary and patented platform enables fast, cost-effective, and accurate analysis of cell-free tumour DNA extracted from blood plasma samples.
  • The partnership leverages the extensive repository of patient samples and deep molecular profiling data available in the iCAN Flagship Project.
  • "The partnership with Genomill aligns with iCAN's mission to leverage the iCAN Discovery Platform for contributions to diagnostic development and for meeting the evolving needs of cancer patients."

Machine Discovery's AI-Powered Solution Selected to Support Consortium on Fusion Energy Research

Retrieved on: 
Tuesday, May 30, 2023
Acceleration, Partnership, Radiation, University, Innovation, Research, OXFORD, Plant, UK Research and Innovation, Content discovery platform, Algorithm, University of York, Security and Prosperity Partnership of North America, AI, Imperial College London, Lithium, Medical device

OXFORD, United Kingdom and SANTA CLARA, Calif., May 30, 2023 /PRNewswire/ -- Machine Discovery's AI-powered Discovery Platform delivers acceleration for compute-intensive optimization and prediction tasks and will be deployed by world-leading teams to support research aimed at the realization of commercial fusion power plants. The Prosperity Partnership project is a multi-year collaboration between First Light Fusion, the University of Oxford, the University of York, Imperial College London, and Machine Discovery. The objective is to explore a new method for creating fusion power that could eventually be scaled to provide safe, clean, and abundant energy.

Key Points: 
  • OXFORD, United Kingdom and SANTA CLARA, Calif., May 30, 2023 /PRNewswire/ -- Machine Discovery's AI-powered Discovery Platform delivers acceleration for compute-intensive optimization and prediction tasks and will be deployed by world-leading teams to support research aimed at the realization of commercial fusion power plants.
  • The Prosperity Partnership project is a multi-year collaboration between First Light Fusion, the University of Oxford, the University of York, Imperial College London, and Machine Discovery.
  • The objective is to explore a new method for creating fusion power that could eventually be scaled to provide safe, clean, and abundant energy.
  • "Our objective is to enable the delivery of fusion energy as fast as possible by providing an AI-powered solution for compute-intensive tasks to achieve significant productivity," said Professor Gianluca Gregori co-founder of Machine Discovery.

Metabolon Launches Bile Acids and Short Chain Fatty Acids Targeted Panels to Advance Understanding of Microbiome and Gut Metabolome in Health and Disease

Retrieved on: 
Tuesday, April 4, 2023
FXR, Diet, Diabetes, Cholesterol, Lipid, Metabolomics, Physiology, Fermentation, TGR5, Research, Biomarker, Microbiota, Colon, Inflammatory bowel disease, Short, SFCA Lignel 46 Coach, Content discovery platform, Risk, Cancer, Medicine, SCFA, Biology, Liver, Extrapyramidal system, Health, Phenotype, Neurology, Disease, Medical imaging, Dietary supplement, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Bile Acids and Short Chain Fatty Acids Targeted Panels that measure microbially-derived metabolites of biological significance to identify biomarkers for the prediction and early detection of disease areas, including oncology, neurology, liver, diabetes, and gastrointestinal, and gut health.

Key Points: 
  • Short Chain Fatty Acids (SCFAs) are produced in the colon by the gut microbiota and are the end products of the anaerobic fermentation of dietary fibers and protein/peptides in the small intestine.
  • Metabolon's Bile Acids Targeted Panel measures 21 metabolites and has been designed specifically to advance pre-clinical research identifying bile-acid related biomarkers in digestive, metabolic, and neurological health.
  • "Metabolon is committed to advancing scientific understanding of the human microbiome and its impact on human health.
  • Our Bile Acids and Short Chain Fatty Acids Targeted Panels address an important need for today's cutting-edge researchers and will help unlock new insights into the complex interplay between diet, gut health, and disease, paving the way for the development of more personalized, targeted therapies."

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
HSV, Pancreatic cancer, Insurance, Herpes simplex virus, University, Partnership, ICI, Survival, Clinical trial, Silicon Valley Bank, Immunotherapy, Nestin, Toxicity, Brain, NSCLC, Lung cancer, Doctor of Philosophy, TWELVE, Rated R, MS, University of Pennsylvania, Silicon, Development, HIV disease progression rates, Patient, Standard of care, Content discovery platform, Administration, HGG, Biology, PD-1, Research, Therapy, CADL, Tumor microenvironment, PD-L1, Valaciclovir, Nivolumab, Prostate cancer, Enlightenment, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Society, Candel, SOC, Cancer, Fellow of the Academy of Medical Sciences, MD

In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.

Key Points: 
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.
  • Importantly, CAN-2409 demonstrated a favorable change in the trajectory of tumor growth in all patients for whom pre-enrollment scans were available.
  • The Company is encouraged by the results and plans to present additional data in Q3 2023.
  • Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.

Bioved Pharmaceuticals, Inc. announces the launch of its proprietary Natural Products for Animal Health, with its Shwan Ayurved™ science

Retrieved on: 
Wednesday, February 15, 2023
Science, Happiness, Human, Solvent, Animal, Disorder, Safety, Plant, Health, Knowledge, SAN, Pesticide, Dietary supplement, Multimedia, Conference, Content discovery platform, Pet, OTC, Dog, Pharmaceutical industry, Ayurveda

SAN JOSE, Calif., Feb. 15, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is pleased to announce the launch of its scientifically validated Natural Animal Health products from the science of Ayurveda.

Key Points: 
  • SAN JOSE, Calif., Feb. 15, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is pleased to announce the launch of its scientifically validated Natural Animal Health products from the science of Ayurveda.
  • Bioved now brings that knowledge and experience to the animal kingdom, under the science of Shwan (Dog) Ayurved™.
  • We take technology and products that have been clinically tested in human beings, and have all the underlying safety and efficacy studies.
  • The herbs or plants used in each of the animal products are extracted by a Bioved US patented method, and standardized and validated by modern biotechnology processes.

Bioved Pharmaceuticals, Inc. announces the launch of its proprietary Natural Products for Animal Health, with its Shwan Ayurved™ science

Retrieved on: 
Wednesday, February 15, 2023
Science, Happiness, Human, Solvent, Animal, Disorder, Safety, Plant, Health, Knowledge, SAN, Pesticide, Dietary supplement, Conference, Content discovery platform, Pet, OTC, Dog, Pharmaceutical industry, Ayurveda

SAN JOSE, Calif., Feb. 15, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is pleased to announce the launch of its scientifically validated Natural Animal Health products from the science of Ayurveda.

Key Points: 
  • SAN JOSE, Calif., Feb. 15, 2023 /PRNewswire/ -- Bioved Pharmaceuticals, Inc. is pleased to announce the launch of its scientifically validated Natural Animal Health products from the science of Ayurveda.
  • Bioved now brings that knowledge and experience to the animal kingdom, under the science of Shwan (Dog) Ayurved™.
  • We take technology and products that have been clinically tested in human beings, and have all the underlying safety and efficacy studies.
  • The herbs or plants used in each of the animal products are extracted by a Bioved US patented method, and standardized and validated by modern biotechnology processes.